One sure sign that specialty pharma sector M&A is on fire: companies in the process of closing acquisition deals are acquiring companies while they wait for antitrust regulators to sign off on their deal. Read More
SAN FRANCISCO – Deal making is continuing its breakneck pace in the life sciences sector with a combined total of almost $50 billion generated from 587 transactions in the first quarter of the year, according to data released last week by Thomson Reuters Recap at the Allicense 2014 meeting. Read More
